Measurement properties and interpretability of the Patient-Reported Impact of Dermatological Diseases (PRIDD) measure

被引:1
|
作者
Pattinson, Rachael [1 ]
Trialonis-Suthakharan, Nirohshah [2 ]
Pickles, Tim [3 ]
Austin, Jennifer [4 ]
Fitzgerald, Allison [4 ]
Augustin, Matthias [2 ]
Bundy, Christine [1 ]
机构
[1] Cardiff Univ, Sch Healthcare Sci, Cardiff, Wales
[2] Univ Med Ctr Hamburg Eppendorf, Inst Hlth Serv Res Dermatol & Nursing, Hamburg, Germany
[3] Cardiff Univ, Ctr Trials Res, Cardiff, Wales
[4] Int Alliance Dermatol Patient Org, Ottawa, ON, Canada
关键词
QUALITY-OF-LIFE; SYSTEMATIC REVIEWS; HOSPITAL ANXIETY; SKIN-DISEASE; ILLNESS PERCEPTIONS; ATOPIC-DERMATITIS; CLINICAL-PRACTICE; OUTCOME MEASURES; GLOBAL BURDEN; PSORIASIS;
D O I
10.1093/bjd/ljae267
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Patient-reported outcome measures (PROMs) are crucial in assessing the impact of dermatological conditions on people's lives, but the existing dermatology-specific PROMs are not recommended for use, according to COSMIN. We developed the Patient-Reported Impact of Dermatological Diseases (PRIDD) measure in partnership with patients. It has strong evidence of content validity, structural validity, internal consistency, acceptability and feasibility. Objectives To test the remaining measurement properties of the PRIDD and establish the interpretability of scores against the COSMIN criteria, using classic and modern psychometric methods. Methods A global longitudinal study consisting of two online surveys administered 2-4 weeks apart was carried out. Adults (>= 18 years of age) living with a dermatological condition were recruited via the International Alliance of Dermatology Patient Organizations' (GlobalSkin) membership network. Participants completed PRIDD, a demographics questionnaire and other related measures, including the Dermatology Life Quality Index. We tested the criterion validity, construct validity and responsiveness (Spearman's rho, independent-samples t-tests and Anova); test-retest reliability [interclass correlation coefficient (ICC)]; measurement error [smallest detectable change or limits of agreement (LoA), distribution-based minimally important change (MIC)]; floor and ceiling effects (number of minimum and maximum scores and person-item location distribution maps), score bandings (kappa coefficient of agreement) and the anchor-based MIC of the PRIDD. Results In total, 504 people with 35 dermatological conditions from 38 countries participated. Criterion validity (rho = 0.79), construct validity (76% hypotheses met), test-retest validity (ICC = 0.93) and measurement error (LoA = 1.3 < MIC = 4.14) were sufficient. Floor and ceiling effects were in the acceptable range (< 15%). Score bandings were determined (kappa = 0.47); however, the anchor-based MIC could not be calculated owing to an insufficient anchor. Conclusions PRIDD is a valid and reliable tool to evaluate the impact of dermatological disease on people's lives in research and clinical practice. It is the first dermatology-specific PROM to meet the COSMIN criteria. These results support the value of developing and validating PROMs with a patient-centred approach and using classic and modern psychometric methods. Further testing of responsiveness and MIC, cross-cultural translation, linguistic validation and global data collection are planned.
引用
收藏
页码:936 / 948
页数:13
相关论文
共 50 条
  • [1] DEVELOPMENT OF THE PATIENT-REPORTED IMPACT OF DERMATOLOGICAL DISEASES (PRIDD) MEASURE
    Pattinson, R.
    Trialonis-Suthakharan, N.
    Austin, J.
    Augustin, M.
    Bundy, C.
    VALUE IN HEALTH, 2022, 25 (01) : S232 - S232
  • [2] Bridging the gap: validating the Patient-Reported Impact of Dermatological Diseases (PRIDD) measure
    Zhang, Junfen
    Yang, Bin
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 (06) : 861 - 861
  • [4] PATIENT-CENTRED DEVELOPMENT AND VALIDATION OF THE PATIENT-REPORTED IMPACT OF DERMATOLOGICAL DISEASES (PRIDD) MEASURE
    Pattinson, Rachael
    Trialonis-Suthakharan, Nirohshah
    Austin, Jennifer
    FitzGerald, Allison
    Augustin, Matthias
    Bundy, Chris
    ACTA DERMATO-VENEREOLOGICA, 2023, 103 : 10 - 10
  • [5] PATIENT-CENTRED DEVELOPMENT AND VALIDATION OF THE PATIENT-REPORTED IMPACT OF DERMATOLOGICAL DISEASES (PRIDD) MEASURE
    Pattinson, Rachael
    Trialonis-Suthakharan, Nirohshah
    Austin, Jennifer
    FitzGerald, Allison
    Augustin, Matthias
    Bundy, Chris
    ACTA DERMATO-VENEREOLOGICA, 2023, 103 : 10 - 10
  • [6] Patient-reported impact of dermatological diseases (PRIDD) measure: Pemphigus and pemphigoid delphi data
    Trialonis-Suthakharan, N.
    Pattinson, R.
    Austin, J.
    FitzGerald, A.
    Yale, M.
    Bundy, C.
    Augustin, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (05) : S115 - S115
  • [7] PATIENT-CENTRED DEVELOPMENT AND VALIDATION OF THE PATIENT-REPORTED IMPACT OF DERMATOLOGICAL DISEASES (PRIDD) MEASURE
    Pattinson, Rachael
    Trialonis-Suthakharan, Nirohshah
    Austin, Jennifer
    FitzGerald, Allison
    Augustin, Matthias
    Bundy, Chris
    ACTA DERMATO-VENEREOLOGICA, 2023, 103 : 10 - 10
  • [8] PATIENT PRIORITISATION OF ITEMS FOR THE NEW PATIENT-REPORTED IMPACT OF DERMATOLOGICAL DISEASES (PRIDD) MEASURE: A DELPHI STUDY
    Pattinson, R.
    Trialonis-Suthakharan, N.
    Gandomkari, Tahmasebi N.
    Lopez, Valencia M. J.
    Austin, J.
    Augustin, M.
    Bundy, C.
    VALUE IN HEALTH, 2022, 25 (07) : S288 - S288
  • [9] Entwicklung des Messinstruments "Patient-Reported Impact of Dermatological Diseases (PRIDD)"
    Trialonis-Suthakharan, Nirohshah
    Pattinson, Rachael
    Austin, Jennifer
    FitzGerald, Allison
    Bundy, Chris
    Augustin, Matthias
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 42 - 42
  • [10] Patient prioritisation of impact items to develop the patient-reported impact of dermatological diseases (PRIDD) measure: European Delphi data
    Trialonis-Suthakharan, N.
    Pattinson, R.
    Tahmasebi Gandomkari, N.
    Austin, J.
    Janus, C.
    Courtier, N.
    Hewitt, R. M.
    Bundy, C.
    Augustin, M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 : 40 - 50